Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Establish the Preferred Dose and to Assess Safety and Overall Response Rate of Avastin in Combination With Concomitant Thoracic Radiation and Chemotherapy (Cisplatin and Etoposide) in Locally Advanced Unresectable Non-squamous Non-small Cell Lung Cancer.

NCT00776698 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00776698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00776698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Establish the Preferred Dose and to Assess Safety and Overall Response Rate of Avastin in Combination With Concomitant Thoracic Radiation and Chemotherapy (Cisplatin and Etoposide) in Locally Advanced Unresectable Non-squamous Non-small Cell Lung Cancer.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2009
Completion date
February 28, 2010
Enrollment
1 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer